TY - JOUR
T1 - Evidence that androgens modulate human thymic T cell output
AU - Olsen, Nancy J.
AU - Kovacs, William J.
N1 - Funding Information:
From the *Divisions of Rheumatology, and †Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, The Pennsylvania State University, College of Medicine, Milton S. Hershey Medical Center, Hershey, PA. Received August 23, 2010, and in revised form October 7, 2010. Accepted for publication October 8, 2010. Reprints: William J. Kovacs, MD, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, The Pennsylvania State University, College of Medicine, Milton S. Hershey Medical Center, H044, 500 University Dr, Hershey, PA 17033-0850. E-mail: [email protected]. These studies were supported by a grant (AG 029999) from the National Institutes of Health. Copyright * 2011 by The American Federation for Medical Research ISSN: 1081-5589 DOI: 10.231/JIM.0b013e318200dc98
PY - 2011/1
Y1 - 2011/1
N2 - Background: The thymus has long been recognized as a target for the actions of androgenic hormones, but it has only been recently recognized that alterations in circulating levels of gonadal steroids might affect thymic output of T cells. We had the opportunity to examine parameters of thymic cellular output in several hypogonadal men undergoing androgen replacement therapy. Methods: Circulating naive (CD4+CD45RA+) T cells were quantitated by flow cytometric analysis of peripheral blood mononuclear cells. Cells bearing T-cell receptor excision circles were quantitated using real-time polymerase chain reaction amplification of DNA isolated from peripheral blood mononuclear cells from healthy men and from hypogonadal men before and after testosterone replacement therapy. Results: CD4+CD45+ (naive) T cells comprised 10.5% of lymphocytes in healthy males; this proportion was greatly increased in 2 hypogonadal men (35.5% and 44.4%). One man was studied sequentially during treatment with physiologic doses of testosterone. CD4+CD45RA+ cells fell from 37.36% to 20.05% after 1 month and to 12.51% after 7 months of normalized androgen levels. In 2 hypogonadal patients, T-cell receptor excision circle levels fell by 83% and 78% after androgen replacement therapy. Conclusions: Our observations indicate that the hypogonadal state is associated with increased thymic output of T cells and that this increase in recent thymic emigrants in peripheral blood is reversed by androgen replacement.
AB - Background: The thymus has long been recognized as a target for the actions of androgenic hormones, but it has only been recently recognized that alterations in circulating levels of gonadal steroids might affect thymic output of T cells. We had the opportunity to examine parameters of thymic cellular output in several hypogonadal men undergoing androgen replacement therapy. Methods: Circulating naive (CD4+CD45RA+) T cells were quantitated by flow cytometric analysis of peripheral blood mononuclear cells. Cells bearing T-cell receptor excision circles were quantitated using real-time polymerase chain reaction amplification of DNA isolated from peripheral blood mononuclear cells from healthy men and from hypogonadal men before and after testosterone replacement therapy. Results: CD4+CD45+ (naive) T cells comprised 10.5% of lymphocytes in healthy males; this proportion was greatly increased in 2 hypogonadal men (35.5% and 44.4%). One man was studied sequentially during treatment with physiologic doses of testosterone. CD4+CD45RA+ cells fell from 37.36% to 20.05% after 1 month and to 12.51% after 7 months of normalized androgen levels. In 2 hypogonadal patients, T-cell receptor excision circle levels fell by 83% and 78% after androgen replacement therapy. Conclusions: Our observations indicate that the hypogonadal state is associated with increased thymic output of T cells and that this increase in recent thymic emigrants in peripheral blood is reversed by androgen replacement.
UR - http://www.scopus.com/inward/record.url?scp=85006167803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006167803&partnerID=8YFLogxK
U2 - 10.2310/JIM.0b013e318200dc98
DO - 10.2310/JIM.0b013e318200dc98
M3 - Article
AN - SCOPUS:85006167803
SN - 1708-8267
VL - 59
SP - 32
EP - 35
JO - Journal of Investigative Medicine
JF - Journal of Investigative Medicine
IS - 1
ER -